[go: up one dir, main page]

ECSP11011022A - Composición estabilizada para el tratamiento de la psoriasis - Google Patents

Composición estabilizada para el tratamiento de la psoriasis

Info

Publication number
ECSP11011022A
ECSP11011022A EC2011011022A ECSP11011022A ECSP11011022A EC SP11011022 A ECSP11011022 A EC SP11011022A EC 2011011022 A EC2011011022 A EC 2011011022A EC SP11011022 A ECSP11011022 A EC SP11011022A EC SP11011022 A ECSP11011022 A EC SP11011022A
Authority
EC
Ecuador
Prior art keywords
alkyl
carboxylic ester
psoriasis
treatment
stabilized composition
Prior art date
Application number
EC2011011022A
Other languages
English (en)
Inventor
William Shifeng Wei
Jianping Pan
Yiping Wang
Sung Hi Jo
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of ECSP11011022A publication Critical patent/ECSP11011022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un ungüento estable al almacenamiento del presente invento que comprende un compuesto de vitamina D, un corticosteroide, y un alquilamino substituido de N,N-di(C1-C8) , un éster carboxílico(C2-C18) alquilo de (C4-C18) un éster carboxílico (C8-C22) alquilo de-(C1-C4)-en una base de ungüento de petrolato y opcionalmente conteniendo aceite mineral, y/o tocoferol. Preferentemente, el compuesto de vitamina D es calcipotriol, el corticosteroide es seleccionado de un grupo que consiste de propionato de clobetasol y dipropionato de betametasona y el alquilamino substituido de N,N-di(C1-C8), éster carboxilico (C2-C18) alquilo de (C4-C18) que contenga dodecil 2-(N,N-dimetilamino)-propionato (DDAIP).
EC2011011022A 2008-10-03 2011-05-03 Composición estabilizada para el tratamiento de la psoriasis ECSP11011022A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19512608P 2008-10-03 2008-10-03

Publications (1)

Publication Number Publication Date
ECSP11011022A true ECSP11011022A (es) 2011-06-30

Family

ID=42073781

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011022A ECSP11011022A (es) 2008-10-03 2011-05-03 Composición estabilizada para el tratamiento de la psoriasis

Country Status (18)

Country Link
US (2) US9220701B2 (es)
EP (1) EP2343978A4 (es)
JP (1) JP5667060B2 (es)
KR (1) KR20110067145A (es)
CN (1) CN102202509A (es)
AU (1) AU2009300331A1 (es)
BR (1) BRPI0920728A2 (es)
CA (1) CA2739376A1 (es)
CL (1) CL2011000722A1 (es)
CR (1) CR20110225A (es)
EC (1) ECSP11011022A (es)
IL (1) IL212062A0 (es)
MX (1) MX2011003568A (es)
NZ (1) NZ592300A (es)
PE (1) PE20110849A1 (es)
RU (1) RU2526162C2 (es)
WO (1) WO2010039251A1 (es)
ZA (1) ZA201103061B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110067145A (ko) * 2008-10-03 2011-06-21 넥스메드 홀딩스 인코포레이티드 건선 치료용 안정화된 조성물
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
WO2014028780A2 (en) * 2012-08-15 2014-02-20 Nexmed Holdings, Inc. Antifungal compounds and methods of use
CN105784902A (zh) * 2016-03-11 2016-07-20 重庆华邦制药有限公司 低浓度丁酸氯倍他松的检测方法
EP3456314A1 (en) 2017-09-14 2019-03-20 Tiofarma B.V. Topical formulation comprising 17-ketolic corticosteroid
WO2020044223A1 (en) * 2018-08-28 2020-03-05 Glenmark Pharmaceuticals Limited Container system and pharmaceutical foam composition comprising betamethasone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980378A (en) * 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
EP1140021B1 (en) * 1998-12-23 2004-08-04 Idea Ag Improved formulation for topical non-invasive application in vivo
SI3146969T1 (en) 1999-04-23 2018-08-31 Leo Pharma A/S Ointment for topical treatment of psoriasis
JP2006511545A (ja) 2002-12-17 2006-04-06 ガルデルマ・ソシエテ・アノニム カルシトリオール及びプロピオン酸クロベタゾールの組み合わせ物を含む医薬組成物
ES2366273T3 (es) * 2003-03-21 2011-10-18 Nexmed Holdings, Inc. Esmalte de uñas antifúngico y procedimiento de utilización.
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
FR2871696B1 (fr) 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
US20060057075A1 (en) 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
EP1959929A4 (en) 2005-12-14 2012-08-15 Zars Pharma Inc COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
KR20110067145A (ko) * 2008-10-03 2011-06-21 넥스메드 홀딩스 인코포레이티드 건선 치료용 안정화된 조성물

Also Published As

Publication number Publication date
CA2739376A1 (en) 2010-04-08
CL2011000722A1 (es) 2012-01-20
ZA201103061B (en) 2012-04-25
CR20110225A (es) 2011-07-18
AU2009300331A1 (en) 2010-04-08
RU2526162C2 (ru) 2014-08-20
EP2343978A4 (en) 2013-11-27
WO2010039251A1 (en) 2010-04-08
RU2011117230A (ru) 2012-11-10
JP2012504607A (ja) 2012-02-23
NZ592300A (en) 2013-01-25
PE20110849A1 (es) 2011-12-02
US20110237558A1 (en) 2011-09-29
CN102202509A (zh) 2011-09-28
EP2343978A1 (en) 2011-07-20
MX2011003568A (es) 2011-06-09
KR20110067145A (ko) 2011-06-21
US9220701B2 (en) 2015-12-29
IL212062A0 (en) 2011-06-30
US20160067266A1 (en) 2016-03-10
JP5667060B2 (ja) 2015-02-12
BRPI0920728A2 (pt) 2015-08-18

Similar Documents

Publication Publication Date Title
ECSP11011022A (es) Composición estabilizada para el tratamiento de la psoriasis
UA106457C2 (ru) Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы
MX2013010471A (es) Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
CU20160100A7 (es) Mezclas y composiciones fungicidas sinérgicas que comprenden 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2(1h)-ona e inhibidores de la biosíntesis de esterol fungicida para el control fúngico
ECSP14004595A (es) 2-tiopirimidinonas
ECSP17057848A (es) Composiciones farmacéuticas para terapia combinada
BRPI0915536A2 (pt) salicilatos acetilados de ácidos graxos e seus usos
BR112012006665A2 (pt) composição, e, método compreendendo aplicar a composição
EA201590730A1 (ru) Способ и стероидная композиция для местного применения
MX2015000138A (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
MX386161B (es) Composición alimenticia para mascotas que comprende ácidos grasos poliinsaturados.
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
SA519401296B1 (ar) تركيبة للتطبيق الموضعي ذات نشاط مضاد للفطريات
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2016009058A (es) Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
BR112015007081A2 (pt) processo contínuo para preparar (met)acrilatos de misturas de álcool, e, uso de um diéster
BR112018001164A2 (pt) composto de fórmula geral, composição farmacêutica e método para o tratamento de uma doença cardiovascular
CR20220343A (es) Agentes terapéuticos selectivos contra el cáncer inhibidores de cdk4/6
CL2011002946A1 (es) Compuestos derivados de tiazoltiadiazol aminopirazol, inhibidores de proteina quinasa c-met; composicion farmaceutica que los comprende y su uso en el tratamiento de diferentes tipos de cancer.
AR096459A1 (es) Composiciones de corticosteroides y método de fabricación
JP2015013966A5 (es)
CR20150635A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
UY35445A (es) Ésteres de testosterona de cadena larga lipoequilibrados para la administración oral
CO2021010485A2 (es) Derivados de pirazolopiridina como inhibidores serina/treonina cinasa que contiene el dominio per-arnt-sim (pask)